Overview

Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

Status:
Not yet recruiting
Trial end date:
2024-03-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream in participants with Hidradenitis Suppurativa. This is a randomized 16-week double-blind, vehicle-controlled (DBVC) study followed by a 16 week open label extension period (OLE) with an active treatment for participants who complete the DBVC period.
Phase:
Phase 2
Details
Lead Sponsor:
Incyte Corporation